Proxy Votes Now

Home › Funds › Direxion Shares ETF Trust › Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF (LABU) proxy voting record 2025-2026

Fund family: Direxion Shares ETF Trust · Filed by Direxion Shares ETF Trust (CIK 1424958) · SEC series S000049373

Ticker: LABU (C000156149)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 967 with, 6 against, 0 abstentions (not counted as with management). Shareholder proposals: 2 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Direxion Shares ETF Trust as a whole

The same two figures as Direxion Shares ETF Trust’s manager page (28,641 ballot items across 25 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsDirexion Shares ETF TrustItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)77.9%94494.4%26,237
Backed environmental and social shareholder proposals at US companiesn/a211.0%620

Where this fund voted differently from most Direxion Shares ETF Trust funds

Each ballot item this fund voted is set against the votes of the other Direxion Shares ETF Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most Direxion Shares ETF Trust funds on all 78 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 96.1% of this fund’s 973 such votes could be given a sector; the other 38 (3.9%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care93560.6%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5830
Say-on-Pay1500
Audit-related1380
Compensation740
Corporate Governance264
Capital Structure180
Extraordinary Transactions50
Environment or Climate11
Other Social Issues11
Shareholder Rights and Defenses10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Moderna, Inc.November 12, 2025$56M20
Moderna, Inc.May 6, 2026$27M50
Twist Bioscience CorporationFebruary 5, 2026$9M50
Travere Therapeutics, Inc.May 19, 2026$4M140
Vertex Pharmaceuticals IncorporatedMay 13, 2026$4M141
Rhythm Pharmaceuticals, Inc.June 24, 2026$3M40
Madrigal Pharmaceuticals, Inc.June 17, 2026$3M70
Revolution Medicines, Inc.June 18, 2026$3M40

Notable votes against management

MeetingCompanyProposalFundMgmt
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

997 ballot items at 144 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Direxion Daily S&P Biotech Bull 3X ETF (LABU) voted at 144 shareholder meetings of 142 companies, on 997 ballot items in all. Where management made a recommendation, the fund followed it on 99.4% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals less often than Direxion Shares ETF Trust's funds as a whole (77.9% against 94.4%). It voted the same way as most Direxion Shares ETF Trust funds on every item where a comparison was possible. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Direxion Shares ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.